Canadian innovation to begin research with support from the Government of Canada
VIDEO B-ROLL AVAILABLE
TORONTO, Sept. 10, 2012 /CNW/ - The following video is available by satellite or by CNW's Video On-Demand web download:
At the unveiling today of a new research facility, the government of Canada announced they are investing funds into the further development of Delivra. Thanks to this investment, Delivra Inc. an innovative bio-medical research company will conduct new research in its laboratory at the National Research Council of Canada Industrial Partnership Facility in Charlottetown, P.E.I.
Through research spanning over six years, Canadian scientist Dr. Joseph Gabriele has worked to develop Delivra, the groundbreaking transdermal delivery system that transports active ingredients through the skin to joints, muscles and other tissues, that, to date, no other topical creams have been able to reach.
As a result, this innovation has been incorporated into Delivra's new line of topical pain relief creams LivRelief, which stands miles apart from the efficacy of other over-the-counter creams.
According to newly released findings from the Canadian Pain Management Report, a study commissioned by Delivra Inc., a staggering 90 per cent of Canadians have purchased pain medication or treatments last year alone. The survey was conducted on the Angus Reid Forum in August 2012.
Results in clinical testing have been unprecedented. The Delivra base in LivRelief products is almost 700 per cent more effective in penetrating deep through the skin - no other topical pain cream in the world can provide such relief deep within the body. Other results include:
- An absorption rate that is six times stronger than its competitors
- Addresses five of the 11 pain pathways in the body, compared to other current topical pain relief creams which only target one pain pathway
- Safe for use on children
Revered Canadian hockey legend Bobby Orr has said it had become a norm for him to live with pain. LivRelief has greatly improved his quality of life.
Other applications for Delivra show great potential for health and beauty products, supplements, medications and anti-aging. In the future, Delivra may be able to provide the same anti-aging benefits in a topical cream that people can only get from cosmetic injectables today.
There are a multitude of potential applications for this technology, with global implications.
Footage of adults experiencing pain, taking oral medication, applying cream
Laboratory footage and unveiling at the National Research Council of Canada Industrial Partnership Facility in PEI
Footage of Bobby Orr playing hockey
Graphic: Canadian Pain Management Report by Delivra: findings
Dr. Joseph Gabriele, President and Chief Scientific Officer, Delivra Inc.
Bobby Orr, Hall of Famer and former NHL player
The Honourable Gary Goodyear, Minister of State for Science and Technology and the Federal Economic Agency for Southern Ontario
The Honourable Robert Ghiz, Premier of Prince Edward Island
The following B-roll is available at the listed times and coordinates:
|DATE OF FEED:||Monday September 10, 2012|
|TIME OF FEED:||1:30 PM EST|
|| GALAXY 3C K06 Slot A (18MHz)
Downlink: 11805.5000 H
Symbol Rate: 15.00
Ms Modulation: DVB S2 8PSK
FEC: ¾ Date Rate: 32.6628
WEB Video Preview and Download link:
|TIME OF POSTING:||Approximately 3:00 PM EST|
|DATE OF POSTING:||Monday September 10, 2012|
All video can be viewed by clicking on the link. Broadcast quality video is available for download by accredited journalists. Please contact [email protected] for access.
STATIONS, FOR FURTHER INFORMATION:
Keka DasGupta at [email protected] or at 416 972 7727.
For technical information DURING the feed, or for assistance with Video On-Demand, please contact CNW at [email protected] or (416) 863-5612.
CNW Video On-Demand http://cnw.pathfireondemand.com provides free, secure and easy-to-use broadcast quality material direct from our website to accredited journalists worldwide.
SOURCE: CNW Broadcast Services
For further information:
CNW VIDEO SERVICES, TORONTO (416) 863-5612